Cell-bank company PBKM invests heavily in cell therapy, shares up 30%

Polski Bank Komórek Macierzystych may consider 2020 a successful year. The Group made acquisitions and improved its financial results. In addition, the first quarter of this year shows increases in the core business generating income. As part of the Strategmed II program, the company implements projects related to the prevention and treatment of civilization diseases.

The number of stored umbilical cord blood or tissue samples in the B2C and B2B segment at the end of Q1 2021 amounted to 402,727, which means an increase of 14.4%.

Last year, PBKM carried out three large acquisitions: in Italy, Germany and Turkey, and in 2021 there were two smaller ones – in the Czech Republic and Slovakia.

The Group invests in the development of services in the field of manufacturing advanced therapy medicinal products ATMP (Advanced Therapy Medicinal Product).

In 2020, Polski Bank Komórek Macierzystych noted an increase in consolidated sales revenues by 12%, to over PLN 211.3 million, generated PLN 29.3 million in EBITDA and PLN 9.3 million in net profit.


Our privacy policy